Dr. David Samadi was born in 1964 and was one of the three children of a businessman and a homemaker. Raised Jewish in Iran, following the Iranian Revolution of 1979 he and his younger brother Dan left Iran for Belgium. Dan and Dr. David Samadi were only 12 and 15 when they had to leave their parents and younger sister behind so they could continue their educations in a safe environment. Paid for by his parents who were still in Iran, he and Dan received their education in Belgium and London before immigrating to the United States for high school.
While in high school in Roslyn, New York, Dr. David Samadi was on the honor roll and the president of his class. He began his higher education at Stony Brook University with a Bachelors in biochemistry before earning his M.D. at Stony Brook School of Medicine in 1994. At Montefiore Medical Center and Albert Einstein College of Medicine, he finished postgraduate training in urology and proctology. In addition, fellowships were completed at Henri Mondor Hospital in France and Memorial Sloan Kettering Cancer Center. He was trained in robotic radical prostatectomy as well as additional proctology training related to oncology during these fellowships.
Dr. David Samadi enjoys using the da Vinci robotic prostatectomy and created his own procedure called the SMART system, or Samadi Modified Advanced Robotic Treatment. This method produces better results with quicker healing, less bleeding, and a smaller risk for postoperative infection due to the smaller incision sites compared to traditional surgery. He has performed over 7,000 robotic surgeries and is the Chief of Robotic Surgery at the New York hospital Lenox Hill. He has been in that position as well as the Chairman of Urology with Lenox Hill since June of 2013.
Dr. David Samadi is a frequent guest and contributor for Fox News and can be seen on Sunday House Call as part of the Medical A-Team. Active on social media, Dr. David Samadi has a strong presence on the internet and frequently communicates with patients and viewers of his segments on Fox News. He also has his own internet channel called SamadiTV where he frequently publishes videos with information about prostate health and other medical topics.
The recipient of many honors, a few of these include being named a New York Super Doctor in 2014, one of America’s Top Doctors in 2008, and a Best Doctor by New York Magazine.
Learn More: prostatecancer911.com/david-samadi/
Friends often designate Eric Lefkofsky, a “serial entrepreneur.” However, with the multiple charitable interests that he and his wife Liz donate time and money to, the correct designation should be “serial philanthropist.” Instead of sitting on the sidelines with the money they have generated, this couple invests considerable funds and ample time into a series of charities in the fields of education, health, human rights, arts and culture, and the development of new technologies for the advancement of those other interests in which they were involved for more info: http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life click here.
As an entrepreneur, Eric started as a carpet salesman in his college years. Eric did not rest after school. He immediately threw himself into business, sometimes failing, sometimes succeeding, but always learning. Today, Eric Lefkofsky works adjunct professor at the University of Chicago Booth School of Business, is a Co-Founder of such businesses as Groupon, Zest Health, Echo Global Logistics, and Inner Workings. He is a Founding Partner in Lightbank, and Co-Founder and CEO pf Tempus. With boundless energy and a wealth of experience in the business community, Eric’s record speaks for itself.
Currently, Eric is concentrating on the creation of databases to facilitate the understanding of how cancer treatments work. Eric, with the force of Liz behind him, helped to found Tempus for the specific purpose of creating an overlay system atop the already existing Medical Record System to facilitate interaction and discovery of how cancer treatments successfully work for one set of people living with cancer but not for others.
Eric came up with the idea following Liz’s breast cancer diagnosis. The couple was stunned to learn while sitting together in the oncologist’s office discussing treatment options, thatoncologists had no access to information to answer questions about why some cancer patients reacted well to treatments while others did not.
The answer to the conundrum, at least for Eric, was to create a system which would allow oncologists to find information regarding cancer treatment success or failures for patients similar to the patient currently sitting in their office. Thus, the concept of the overlay system that would sift through medical records, find similar cases, and analyze the correct treatment bore the fruit of Tempus.
When Dr. Clay Siegall founded his company, Seattle Genetics, in 1998, he has acquired over twenty years experience in cancer research. This experience has set the goals of Seattle Genetics to give Doctors better cancer treatment tools, and to help treat cancer patients with better therapies for everyday living.
These goals are personal for Clay as he watched his own father pass away from suffering with cancer for years. As a young man, this experience has had a profound impact on Clay, so he dedicated himself to finding a more advanced way of treating cancer.
Under Clay Siegall‘s leadership, he has raised 1.2 billion to date to fund cancer research and treatment. One cancer treatment that has been generated is ADCETRIS. This medicine is an ADC (antibody drug conjugate). ADC target only cancer cells, and will leave healthy cells intact. This is significant for cancer patients as it will decrease healing time and lessen side effects often seen in traditional cancer treatments.
ADCETRIS has currently been approved in over 64 countries as a viable treatment option and Seattle Genetics has entered into partnerships with other pharmaceutical companies sharing the ADC technology. Right now there are over 20 ADCs been produced thanks to this partnership.
Dr. Siegall entered the workforce years ago, first working for National Cancer Institute, National Institutes of Health as a researcher, and for Bristol-Myers Squibb Pharmaceutical Research Institute before building his own business.
Dr. Siegall is passionate about cancer treatment and the overall medical treatment of cancer patients. That is why Clay also serves on the boards of Alder BioPharmaceuticals and Ultragenyx Pharmaceutical. And on the Board of Directors for Washington Roundtable. Dr. Siegall has received his Bachelors of Science in Zoology from the University of Maryland, and his PhD in Genetics from George Washington University.